Real-World Mobocertinib Data Lay Groundwork for Further EGFR+ NSCLC Research
Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.
Leora Horn, MD, associate professor of cancer research, Vanderbilt Ingram Cancer Center, associate professor of medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.
Recent data observed in patients with EGFR-positive non–small cell lung cancer (NSCLC) shows the power of real-world data in the field, explains Horn. Although the data are not perfect because database information can vary, information from real-world studies has the potential to set the bar for clinical trial research.
According to Horn, real-world data does sometimes reinforce what has been previously observed with targeted therapies in the clinical trial setting. This gives oncologists gratification that patients are receiving good care.
Horn also explains that clinical trials are still important and oncologists across the county should work in collaboration to get patients with EGFR-positive NSCLC and other forms of lung cancer enrolled in clinical trials.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
August 20th 2024Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.
Read More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
